Talk:WuXi AppTec

Companies Start‑class Low‑importance

This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles

Start This article has been rated as Start-class on Wikipedia's content assessment scale.

Low This article has been rated as Low-importance on the project's importance scale.

WikiProject Companies To-do:

Here are some tasks awaiting attention:

Article requests : Wikipedia:Requested articles/Business and economics/Companies
Assess : Category:Unassessed company articles
Copyedit : Category:Company articles needing attention
Infobox : Category:Company articles needing infoboxes
Maintain : Portal:Companies
Stubs : Help expand stub articles located at Category:Company stubs
Other :
- Tag company articles with the {{portal|Companies}} template
- Tag company talk pages with the {{WikiProject Companies}} project banner
- Answer requests for comments

The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.

AM WuXi (talk · contribs) has been paid by WuXi AppTec on their behalf.

Updates to the article

Hi, as the declared COI editor for WuXi AppTec, I would like to suggest some updates to the article based on the company's activities in recent years. Please add:

In the History section - In 2019, WuXi AppTec acquired Pharmapace, a clinical services company in San Diego.^[1] In 2021, WuXi STA purchased a Bristol Myers Squibb drug product manufacturing facility in Switzerland,^[2] WuXi AppTec acquired the UK-based R&D contract company, OXGENE,^[3] and WuXi ATU opened a testing center in Philadelphia.^[4]

Additionally, the different WuXi AppTec entities are inaccurate in the article. See this source to explain the rename and these entities under the WuXi AppTec umbrella. As far as I understand, based on the guidelines, this would be an uncontroversial edit for me to do. As it is a bit labor-intensive, I am happy to go in and do it myself with the community's approval.

References

^ Adams, Ben (8 May 2019). "China's WuXi AppTec buys up U.S. Pharmapace, boosting biometrics offering". fiercebiotech.com.
^ "WuXi STA completes acquisition of Bristol Myers Squibb manufacturing facility in Switzerland". 3 August 2021.
^ "OXGENE Eyes Further Growth in Cell and Gene Therapy Services after Acquisition by WuXi AppTec". genedgenews.com. 3 March 2021.
^ MacDonald, Gareth (7 December 2021). "WuXi ATU opens cell and gene therapy testing center". bioprocessintl.com.

Thank you very much.AM WuXi (talk) 14:46, 6 December 2023 (UTC)[reply]

[1] Adams, Ben (8 May 2019). "China's WuXi AppTec buys up U.S. Pharmapace, boosting biometrics offering". fiercebiotech.com.

[2] "WuXi STA completes acquisition of Bristol Myers Squibb manufacturing facility in Switzerland". 3 August 2021.

[3] "OXGENE Eyes Further Growth in Cell and Gene Therapy Services after Acquisition by WuXi AppTec". genedgenews.com. 3 March 2021.

[4] MacDonald, Gareth (7 December 2021). "WuXi ATU opens cell and gene therapy testing center". bioprocessintl.com.

[1]

[2]

[3]

[4]